Welcome to today's Medical News Today News Alert containing today's medical news headlines for your chosen categories. You will only receive these alerts when new news is available for your chosen categories.
To unsubscribe from our news alerts, or to alter any of your subscription details (name,e-mail address etc) please see
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
----------------------------------------------
** BREAST CANCER News **
Breast Cancer Patients Face Preoperative Options
http://www.medicalnewstoday.com/articles/116916.php
A comprehensive healthcare newsletter from the American Society of Breast Disease summarizes options for preoperative systemic therapy for many breast cancer patients. The ASBD Breast Healthcare Update - Systemic Chemotherapy for Breast Cancer: Issues in Preoperative and Adjuvant Treatment reviews current issues and controversies in preoperative and adjuvant treatment of breast cancer.
----------------------------------------------
** CANCER / ONCOLOGY News **
Preliminary Cerepro (R) Phase III Results Meet Primary Endpoint - Operable Primary Malignant Glioma
http://www.medicalnewstoday.com/articles/116938.php
Ark Therapeutics Group plc (AKT:LSE) announces that the preliminary analysis of Study 904, a Phase III study of Cerepro (R), its novel gene-based therapy being developed as an Orphan Drug for the treatment of operable primary malignant glioma, demonstrates that the trial has met its primary endpoint.
FDA Clears The Pathwork(R) Tissue Of Origin Test For Hard-To-Identify Tumors
http://www.medicalnewstoday.com/articles/116930.php
Pathwork Diagnostics, Inc., a molecular diagnostics company focused on oncology, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Pathwork® Tissue of Origin Test for use in determining the origin of uncertain tumors.
California Communities Host Conferences To Discuss Cancer And Hispanics
http://www.medicalnewstoday.com/articles/116928.php
Two communities in California will be addressing cancer among Hispanics. Summaries of news coverage previewing the events appear below.<ul><li class="AdvisoryBullet">Santa Cruz County: A daylong forum on Aug.
MabThera Filed In The EU For Treatment Of Most Common Leukaemia In Adults
http://www.medicalnewstoday.com/articles/116925.php
Submission Based on Phase III Study Showing Superior Results for MabThera in Chronic Lymphocytic Leukaemia (CLL) When Added to Standard Chemotherapy Today, Roche submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for the use of its biotechnology drug MabThera (rituximab) as first-line treatment of chronic lymphocytic leukaemia, the most common form of adult leukaemia.
Breast Cancer Patients Face Preoperative Options
http://www.medicalnewstoday.com/articles/116916.php
A comprehensive healthcare newsletter from the American Society of Breast Disease summarizes options for preoperative systemic therapy for many breast cancer patients. The ASBD Breast Healthcare Update - Systemic Chemotherapy for Breast Cancer: Issues in Preoperative and Adjuvant Treatment reviews current issues and controversies in preoperative and adjuvant treatment of breast cancer.
Newsweek Examines Emerging Field Of Oncofertility
http://www.medicalnewstoday.com/articles/116901.php
<BR /><A href="http://www.newsweek.com/id/148983" target=_new><CITE>Newsweek</CITE></A> recently examined the "bourgeoning world of oncofertility," which specializes in assisted reproduction for women who are undergoing radiation or chemotherapy.
UM Partners With Seed-One Ventures To Form New Company To Develop And Market Broad-Based Therapies For Cancer And Other Diseases
http://www.medicalnewstoday.com/articles/116891.php
The University of Miami Miller School of Medicine and Seed-One Ventures announce the formation of Heat Biologics Inc. to develop two related platform technologies which introduce a novel lung cancer vaccine and asthma therapy, with potential applications in the treatment of a number of other inflammatory diseases.
Poniard Pharmaceuticals To Present At The 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
http://www.medicalnewstoday.com/articles/116868.php
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, announced that the Company will present information on platinum resistance at the Fourth Annual Moores UCSD Cancer Center Translational Oncology Symposium on Friday, August 1, in San Diego.
FDA Clears The Pathwork(R) Tissue Of Origin Test For Hard To Identify Tumors
http://www.medicalnewstoday.com/articles/116865.php
Pathwork Diagnostics, Inc., a molecular diagnostics company focused on oncology, announced that the U.S. Food and Drug Administration (FDA) has cleared its Pathwork(R) Tissue of Origin Test for use in determining the origin of uncertain tumors.
Lymphoma Research Foundation Announces Its 2008 Research Grant Recipients
http://www.medicalnewstoday.com/articles/116860.php
As part of its ongoing effort to find a cure for lymphoma, the Lymphoma Research Foundation (LRF) proudly announces the 2008 Research Grant Recipients of its Post-Doctoral Fellowships and Clinical Investigator Career Development Awards, LRF's two cornerstone research programs.
The Latest On Premier Science In Medical Oncology At The 33rd ESMO Congress, Stockholm, Sweden, Sept. 12-16, 2008
http://www.medicalnewstoday.com/articles/116819.php
<b>Congress Highlights</b>Some of the highlights that will be presented during the educational and scientific program at Europe's premier medical oncology meeting include:<ul><li> Molecular analysis for target discovery: Identification of 'Achilles' heel' MicroRNa, SiRNA libraries</b>Protein array </li><li> Innovation in breast cancerModulation of resistance to anti-Her2 therapiesEvaluation of predictive markers on circulating tumor cellsNew targets for triple negative tumorsStem cell as a potential targetTools in daily clinical practice to improve treatment</li><li> Tailoring therapy in lung cancerMedical implications of resistance to EGFRPersonalized cancer therapies for non-EGFR receptor-dependent tumors</li><li> New pathways in targeted therapy IGF-1, PI 3, PARP, Met</li><li> Optimal integration of newer agents in the treatment of advanced CRCGenomic and pharmacogenetic markers for treatment decisionUpfront sequential vs.
Lab Study Shows Methadone Breaks Resistance In Untreatable Forms Of Leukemia
http://www.medicalnewstoday.com/articles/116688.php
Researchers in Germany have discovered that methadone, an agent used to break addiction to opioid drugs, has surprising killing power against leukemia cells, including treatment resistant forms of the cancer.
Immunotherapy In High-Risk Pediatric Sarcomas Shows Promising Response
http://www.medicalnewstoday.com/articles/116687.php
Based on a pilot study in children with sarcoma, researchers at the National Institutes of Health (NIH) believe that immunotherapy could prove beneficial in treating high-risk forms of this cancer.
----------------------------------------------
** CERVICAL CANCER / HPV VACCINE News **
Haitian Women Living In Miami Less Likely Than Black, White Women To Have Had Pap Test, Research Shows
http://www.medicalnewstoday.com/articles/116927.php
Only 44% of Haitians over age 18 who live in the Little Haiti neighborhood in Miami have had a Pap test, compared with 84% of black women and 84% of white women, according to a study by researchers at the <a href="http://www6.
Audit Finds Reported Cervical Cancer Cases In Maryland Deliberately Altered In State Database
http://www.medicalnewstoday.com/articles/116900.php
<BR />The number of reported cervical cancer cases in Maryland was deliberately overreported in a state database that records the number of cancer cases statewide, according to a recent audit conducted by the <A href="http://dls.
----------------------------------------------
** COLORECTAL CANCER News **
No news for this category today.
----------------------------------------------
** LUNG CANCER News **
No news for this category today.
----------------------------------------------
** LYMPHOMA / LEUKEMIA News **
MabThera Filed In The EU For Treatment Of Most Common Leukaemia In Adults
http://www.medicalnewstoday.com/articles/116925.php
Submission Based on Phase III Study Showing Superior Results for MabThera in Chronic Lymphocytic Leukaemia (CLL) When Added to Standard Chemotherapy Today, Roche submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for the use of its biotechnology drug MabThera (rituximab) as first-line treatment of chronic lymphocytic leukaemia, the most common form of adult leukaemia.
Aegera Initiates A Fifth Phase 1 And 2 Clinical Trial For AEG35156
http://www.medicalnewstoday.com/articles/116863.php
Aegera Therapeutics Inc. is pleased to announce the dosing of the first patient in a fifth phase 1 and 2 clinical oncology study of AEG35156, a second generation antisense therapeutic targeting XIAP, a key member of the Inhibitor of Apoptosis protein family.
Genmab And GlaxoSmithKline Announce Positive Top-Line Results In Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
http://www.medicalnewstoday.com/articles/116862.php
Genmab A/S (OMX: GEN) and GlaxoSmithKline (LSE and NYSE: GSK) announced positive top-line results from an interim analysis of the Phase III pivotal study evaluating ofatumumab (HuMax-CD20(R)) to treat two groups of chronic lymphocytic leukemia (CLL) patients with high unmet medical need.
Lymphoma Research Foundation Announces Its 2008 Research Grant Recipients
http://www.medicalnewstoday.com/articles/116860.php
As part of its ongoing effort to find a cure for lymphoma, the Lymphoma Research Foundation (LRF) proudly announces the 2008 Research Grant Recipients of its Post-Doctoral Fellowships and Clinical Investigator Career Development Awards, LRF's two cornerstone research programs.
Lab Study Shows Methadone Breaks Resistance In Untreatable Forms Of Leukemia
http://www.medicalnewstoday.com/articles/116688.php
Researchers in Germany have discovered that methadone, an agent used to break addiction to opioid drugs, has surprising killing power against leukemia cells, including treatment resistant forms of the cancer.
----------------------------------------------
** PROSTATE / PROSTATE CANCER News **
David B. Samadi, MD, Demonstrates Robotic Prostate Surgery During Live Webcast, August 13, 2008
http://www.medicalnewstoday.com/articles/116887.php
The Mount Sinai Medical Center and Intuitive Surgical, Inc. will offer a live webcast on OR-Live.com featuring David B. Samadi, M.D., Chief of Robotics and Minimal Invasive Surgery in the Department of Urology at Mount Sinai on August 13, 2008 at 5:00 p.
-------------------------------------------------------------
You are receiving this news alert e-mail because you subscribed via an online form on our web site. If you wish to unsubscribe, please visit
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
No comments:
Post a Comment